Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
SWOG Cancer Research Network
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03887702
This phase III trial studies the effect of tenofovir alafenamide in preventing liver
complications in patients with current or past hepatitis B virus (HBV) who are receiving
anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing
therapy for cancer are at an increased risk for changes in the liver which could be minor or
severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may
help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer
therapy for solid tumors.
complications in patients with current or past hepatitis B virus (HBV) who are receiving
anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing
therapy for cancer are at an increased risk for changes in the liver which could be minor or
severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may
help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer
therapy for solid tumors.
Intervention
Entecavir, Tenofovir Disoproxil Fumarate, Best Practice, Tenofovir Alafenamide
Condition
Hepatitis B Infection, Malignant Solid Neoplasm
Investigators
Jessica P Hwang